Published in J Biol Chem on June 03, 2003
Multi-faceted role of HSP40 in cancer. Clin Exp Metastasis (2009) 1.11
Tid1, a cochaperone of the heat shock 70 protein and the mammalian counterpart of the Drosophila tumor suppressor l(2)tid, is critical for early embryonic development and cell survival. Mol Cell Biol (2004) 0.95
Functional genetic screen for genes involved in senescence: role of Tid1, a homologue of the Drosophila tumor suppressor l(2)tid, in senescence and cell survival. Mol Cell Biol (2004) 0.92
Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) (2013) 0.92
Molecular mechanism of hTid-1, the human homolog of Drosophila tumor suppressor l(2)Tid, in the regulation of NF-kappaB activity and suppression of tumor growth. Mol Cell Biol (2005) 0.88
Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice. J Invest Dermatol (2012) 0.86
Tid1 is a Smad-binding protein that can modulate Smad7 activity in developing embryos. Biochem J (2006) 0.79
In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor. J Transl Med (2010) 0.75
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res (2007) 1.65
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem (2002) 1.56
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res (2011) 1.53
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene (2003) 1.49
Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer (2004) 1.45
The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene (2002) 1.44
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res (2008) 1.44
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res (2006) 1.41
Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol (2008) 1.25
Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res (2004) 1.22
Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res (2009) 1.19
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med (2007) 1.12
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther (2006) 1.08
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res (2008) 1.06
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem (2003) 1.05
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res (2003) 1.03
Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res (2007) 1.03
Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res (2005) 1.02
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem (2004) 1.00
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res (2004) 0.99
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res (2002) 0.98
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res (2007) 0.98
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS One (2010) 0.98
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol (2008) 0.97
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther (2007) 0.96
Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol (2003) 0.95
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. J Cell Physiol (2006) 0.95
Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer (2008) 0.94
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer (2003) 0.94
Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med (Berl) (2012) 0.93
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res (2010) 0.93
NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res (2010) 0.93
Evaluation of MicroRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in northwestern Hungary. Anticancer Res (2013) 0.90
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol (2006) 0.90
cDNA-array profiling of melanomas and paired melanocyte cultures. J Cell Physiol (2006) 0.90
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer (2012) 0.89
The synergistic activity of thyroid transcription factor 1 and Pax 8 relies on the promoter/enhancer interplay. Mol Endocrinol (2002) 0.89
The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis (2014) 0.88
Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) (2006) 0.88
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther (2006) 0.88
Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol (2004) 0.88
Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol (2003) 0.88
Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene (2005) 0.87
Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J Transl Med (2009) 0.86
LMNA knock-down affects differentiation and progression of human neuroblastoma cells. PLoS One (2012) 0.86
Loss of E-cadherin in the vicinity of necrosis in colorectal carcinomas: association with NFkappaB expression. Int J Oncol (2007) 0.85
Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) (2002) 0.85
Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors. PLoS One (2012) 0.85
Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol (2012) 0.83
Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Anticancer Res (2007) 0.83
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Can J Physiol Pharmacol (2010) 0.82
ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) (2006) 0.81
Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol (2010) 0.81
Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med (2006) 0.81
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Res (2007) 0.81
Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression. J Cardiovasc Pharmacol (2004) 0.81
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res (2004) 0.81
A melanoma immune response signature including Human Leukocyte Antigen-E. Pigment Cell Melanoma Res (2013) 0.81
Skin cancer risk factors among primary school children: investigations in Western Hungary. Prev Med (2010) 0.80
The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09. J Transl Med (2010) 0.80
Human glioblastoma ADF cells express tyrosinase, L-tyrosine hydroxylase and melanosomes and are sensitive to L-tyrosine and phenylthiourea. J Cell Physiol (2006) 0.80
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother (2010) 0.80
Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med (2008) 0.80
Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain. Int J Cancer (2003) 0.80
Targeting endothelin axis in cancer. Cancer Treat Res (2004) 0.80
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. J Cell Physiol (2011) 0.79
Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood) (2006) 0.79
Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene. J Exp Clin Cancer Res (2008) 0.78
Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer. J Cell Physiol (2005) 0.78
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. Anticancer Res (2002) 0.78
Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol (2004) 0.77
Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. Can J Physiol Pharmacol (2010) 0.77
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res (2005) 0.76
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol (2004) 0.76
Prognostic factors in Hungarian breast cancer patients. Anticancer Res (2007) 0.76
Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials . Int J Clin Pharmacol Ther (2016) 0.75
The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2007-08. J Transl Med (2009) 0.75
[Skin cancer risk factors in childhood: findings of a survey in an Italian area characterized by atypical migration]. Epidemiol Prev (2009) 0.75
[Skin cancer risk factors in childhood: findings of a survey conducted within Italian areas with a different incidence of melanoma]. Epidemiol Prev (2011) 0.75
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) (2002) 0.75
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003. Tumori (2004) 0.75